Biopharma company Enveric Biosciences (NASDAQ: ENVB) has shared new findings involving the first-ever isolation of a specific enzyme from the cane toad, plus the successful development of a bioproduction platform for the isolation and pharmacological screening of novel molecules belonging to the indolethylamine family.

Researchers at the University of Calgary led by Enveric’s CIO Dr. Peter Facchini successfully isolated a novel indolethylamine N-methyltransferase (RmNMT) from cane toads, representing the first alkaloid biosynthetic gene and cognate enzyme isolated from the species.

Interestingly, functionally similar enzymes are found in mammals and fungi too. Yet only the RmNMT found on the toads, because of their efficiency and promiscuity, qualifies as suitable for the bioproduction of novel indolethylamine derivatives. 

The discovery has propelled the creation of an innovative platform for the …

Full story available on